Clinical trials: Portal Vein Thrombosis
HepatoCellular Carcinoma
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
Hepatocellular carcinoma (HCC) is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3.
- Trial name
- RHCC (NCT02309788)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Contraceptive Usage, Coagulation
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills
A randomized study is to learn more about how a supplement called DHEA (dehydroepiandrosterone) affects clotting factors in women taking combined oral contraceptive pills.
- Trial name
- COC+DHEA (NCT03418363)
- Testing
- DHEA Oral Capsule
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Pulmonary Embolism, Venous Thrombosis
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Observational. Retrospective cohort.
- Conditions
- Pulmonary Embolism, Venous Thrombosis, Portal Thrombosis
- Trial name
- NCT02597218
- Where
- Argentina
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Hepatocellular Carcinoma
Neoadjuvant Radiotherapy for HCC Involving Type I PVTT
The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially those with type I or II PVTT.
- Trial name
- NCT04025437
- Testing
- Hepatectomy alone, Neoadjuvant radiotherapy
- Where
- China
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University